Highest-materiality recent filing
Each outstanding share converted into the right to receive $18.50 in cash; total transaction valued at approximately $376.8 million.
Simulations Plus shareholders approve Altaris acquisition; pending French approval
Special Meeting on Aug 27, 2026: 14,735,712 votes for vs 771,288 against to adopt merger with Altaris affiliate.
Simulations Plus HSR waiting period expires for Altaris acquisition; close expected H2 2026
HSR waiting period for Altaris acquisition expired Aug 13, 2026, clearing one regulatory hurdle.
Simulations Plus Q3 revenue $21.9M (+7% YoY); merger with Altaris on track
Q3 revenue $21.9M (+7% YoY); software flat at $12.6M, services up 20% to $9.3M.
Simulations Plus to be acquired by Altaris affiliate for $18.50 per share in all-cash deal
Each common share will be converted into $18.50 in cash, representing a premium to the last close.
Simulations Plus to be acquired by Altaris for $375M, $18.50/share cash
All-cash acquisition at $18.50/share, 26% premium to 60-day VWAP.
Total revenue $24.3M (+8% YoY); software $14.6M (+9%), services $9.7M (+8%). Gross margin improved to 66% from 59%.
Simulations Plus shareholders OK 38% equity plan share increase; director with high withhold vote
Shareholders approved amendment to 2021 Equity Incentive Plan, raising authorized shares from 2.5M to 3.45M (38% increase).
Simulations Plus Q1 revenue down 3% to $18.4M; adjusted EPS falls to $0.13
Revenue $18.4M (-3% YoY); software $8.9M (-17%), services $9.5M (+16%).
Simulations Plus enters new employment agreements; CEO base salary $547,700, target bonus 75%
CEO Shawn O'Connor's amended agreement: base salary $547,700, target cash bonus 75% of base, target stock options 50,000.
Simulations Plus Q4 revenue down 6% to $17.5M, posts net loss; reaffirms FY2026 guidance
Q4 total revenue $17.5M (-6% YoY); software $9.0M (-9%); services $8.4M (-3%).
Simulations Plus provides preliminary FY2025 revenue of $79.1M and FY2026 guidance of $79-82M
Preliminary FY2025 revenue $79.1M (+13% YoY); adjusted diluted EPS guidance $1.03-$1.10 for FY2026.
Simulations Plus dismisses Grant Thornton, reappoints RSJ as auditor citing 10-Q timeline concerns
Dismissed Grant Thornton LLP on July 9, 2025; re-hired Rose, Snyder & Jacobs LLC for FY2025.
Simulations Plus Q3 net loss $67.3M on $77.2M impairment; adjusted EPS $0.45 tops year-ago $0.27
Total revenue $20.4M (+10% YoY); software $12.6M (+6%), services $7.7M (+17%).
Simulations Plus reschedules Q3 earnings to July 14, reaffirms preliminary revenue guidance
Conference call moved to Monday, July 14, 2025 at 5 p.m. ET; results expected before market open July 15.
Simulations Plus pre-announces Q3 revenue $19-20M; lowers FY2025 guidance to $76-80M
Preliminary Q3 FY2025 revenue expected between $19M and $20M.
Simulations Plus Q3 FY2025 revenue prelim $19-20M; full-year guidance cut to $76-80M
Preliminary Q3 FY2025 revenue expected $19-20M, subject to final adjustment.
John DiBella appointed Chief Revenue Officer; Daniel Szot departs at end of fiscal Q3 for other opportunities.
Simulations Plus replaces auditor RSJ with Grant Thornton for FY2025
Dismissed Rose, Snyder & Jacobs (RSJ) as auditor effective April 15, 2025.
Simulations Plus Q2 revenue $22.4M (+23% YoY); EPS $0.15 vs $0.20; adjusted EPS $0.31
Total revenue $22.4M, +23% YoY; software $13.5M (+16%), services $8.9M (+34%).
Simulations Plus shareholders elect all five directors, ratify auditor, approve say-on-pay
All five director nominees elected: Dr. Weiner, Dr. Woltosz, Dr. Paglia, Dr. LaVange, Sharlene Evans; broker non-votes of 1,257,913.
Simulations Plus Q1 FY25 revenue up 31% to $18.9M; software up 41%, adjusted EPS $0.17
Total revenue $18.9M (+31% YoY); software revenue $10.7M (+41%) driven by MonolixSuite (+43%) and QSP (+40%).
Simulations Plus FY2024 revenue $70M (+18% YoY); guides FY2025 $90-93M rev, adj. EPS $1.07-1.20
Q4 FY2024 revenue $18.7M (+19% YoY); diluted EPS $0.04, adjusted diluted EPS $0.06.
Simulations Plus Announces Leadership Changes and Business Unit Restructuring
Steven Chang promoted to President, Quantitative Systems Pharmacology, effective August 30, 2024.
Simulations Plus Q3 revenue $18.5M (+14% YoY), EPS $0.15; discontinues dividend
Total revenue $18.5M, up 14% YoY; net income $3.1M vs $4.0M; diluted EPS $0.15 vs $0.20.
All-cash purchase of Pro-ficiency for $100M; funded from existing cash and investments; no debt retained after deal.
Simulations Plus presents at BTIG conference; filing contains no financial details
Presenting at BTIG Digital Health Forum on May 21, 2024 with Q2 FY24 update.
Simulations Plus Q2 rev $18.3M (+16%); EPS $0.20 flat; FY guidance reaffirmed
Revenue $18.3M (+16% YoY); software $11.6M (+11%), services $6.7M (+27%).
Simulations Plus presents at Oppenheimer conference with Q1 FY24 update presentation
Participating at Oppenheimer investor conference on February 13, 2024.
Simulations Plus shareholders approve 61% increase in equity plan shares to 2.5M
Shareholders approved increasing authorized shares under 2021 Equity Incentive Plan from 1,550,000 to 2,500,000 (61% increase).
Simulations Plus Q1 revenue $14.5M (+21% YoY), EPS $0.10; maintains FY guidance; appoints COO
Q1 revenue $14.5M (+21% YoY), diluted EPS $0.10 (vs $0.06), adjusted EBITDA $3.4M (23% of revenue).
SLP files 8-K with BTIG conference presentation; no specific data in filing text
Company participating at BTIG Digital Health Forum on November 20, 2023.
Investor Day held on November 14, 2023; presentation furnished as exhibit.
Simulations Plus enters amended employment agreements with five top executives
CEO Shawn O'Connor: base salary $514,800, target cash bonus 75% of base (up to $75K discretionary plus 7,500 extra options).
Simulations Plus Q4 revenue up 33% to $15.6M; guides FY2024 revenue $66-69M
Q4 total revenue $15.6M (+33% YoY); software revenue $9.3M (+59%), services $6.3M (+8%).
Simulations Plus to present at BTIG conference; Q3 FY23 deck posted
Participating in BTIG investor conference from July 11-13, 2023.
Q3 revenue $16.2M (+9% YoY); diluted EPS $0.20 (flat); adjusted EBITDA $6.5M (40% margin).
Simulations Plus acquires Immunetrics for $15.5M+$8M earnout to expand QSP capabilities
Total consideration up to $23.5M: $15.5M cash at closing (incl. $1.8M holdback) plus up to $8M earnout based on 2023-2024 revenue.
Simulations Plus Q2 revenue up 6% to $15.8M; maintains FY23 guidance
Revenue $15.8M (+6% YoY); software $10.5M (+7%), services $5.3M (+4%).
Simulations Plus presents at Raymond James conference; Q1 FY23 update included
Furnished presentation for Raymond James 44th Annual Institutional Investors Conference on March 7, 2023.
Simulations Plus shareholders approve increase in 2021 Plan shares to 1.55M
All five director nominees elected with over 99% of votes cast; broker non-votes 1.3M.
Simulations Plus launches $20M accelerated share repurchase under $50M buyback plan
Enters ASR with Morgan Stanley; initial payment of $20M, receives ~409k shares.
Simulations Plus Q1 revenue down 4% to $12M; EPS falls to $0.06; announces $50M buyback
Q1 revenue $12.0M (-4% YoY); diluted EPS $0.06 vs $0.15; net income $1.2M.
Simulations Plus furnishes Q4 FY22 investor presentation at conference
Presented at Hidden Gems Conference on November 7, 2022.
Simulations Plus sets FY2023 director pay at $165K; appoints lead independent director
Non-executive directors receive $165K annually ($120K stock grants, $45K cash stipend).
Simulations Plus FY2022 revenue $53.9M (+16%), EPS $0.60; guides FY2023 rev $59.3M-$62.0M
Full-year revenue $53.9M (+16% YoY); diluted EPS $0.60 (+28% YoY).
Simulations Plus declares $0.06 quarterly dividend, payable Nov 7, 2022
Quarterly cash dividend of $0.06 per share declared by Board of Directors.
Simulations Plus to present at Baird 2022 Global Healthcare Conference on Sep 14
Presentation posted on company website in the Investors section.
Simulations Plus Q3 revenue $15.0M (+17%), EPS $0.20, declares $0.06 dividend
Total revenue $15.0M (+17% YoY); software $9.7M (+16%), services $5.3M (+19%).
Filed Exhibit 99.1 contains only a title slide indicating a Q2 FY22 update.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
On October 6, 2026, following the consummation of the Merger, the Board appointed Paul Labute as President of the Company.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
Erik Guffrey , currently Chief Technology Officer, Adaptive Learning & Insights and Medical Communications Products, assumes the new role of Co-Chief Product and Technology Officer.
Dr. Jonathan Chauvin , currently Business Unit Co-President, Clinical Pharmacology & Pharmacometric Solutions, assumes the new role of Co-Chief Product and Technology Officer.
Josh Fohey , currently Senior Vice President, Operations, assumes the new role of Chief Operating Officer.
On May 30, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Simulations Plus, Inc. (the “Company”) appointed John DiBella as Chief Revenue Officer of the Company, effective immediately.
Steven Chang , currently Business Unit President, Quantitative Systems Pharmacology Solutions, assumes the new role of Global Head of Strategic Alliances.
Max materiality 0.90 · Median 0.60 · Most common event earnings